Answers are grounded in this paper and cite their sources.
Background/Objectives: Available zinc biomarkers do not reliably identify children likely to benefit from supplementation. This review examined biomarker responsiveness to supplementation, associations with growth, and evidence for differential treatment benefit. Methods: This critical narrative review examined ten purposively selected sentinel reports from eight study families, predominantly involving preterm infants and children aged ≤3 years. Reports were identified through a structured PubMed/MEDLINE search of 2021–2025 publications and appraised using design-specific Joanna Briggs Institute tools. Results: Serum or plasma zinc often increased after supplementation without a corresponding improvement in growth. Community-based growth findings were inconsistent; the modest benefit observed with a multinutrient formulation could not be attributed to zinc alone. Neonatal observational findings were mixed and could not establish a causal effect on growth. Evidence from studies involving children with cystic fibrosis or chronic kidney disease was insufficient to establish a growth benefit. Within the selected corpus, no baseline biomarker was validated as a predictor of growth response. Sample sizes and follow-up limited conclusions about safety, particularly uncommon or delayed adverse effects. Conclusions: Identifying the zinc-responsive child may be best approached through a multidimensional assessment integrating standardized biomarkers, longitudinal growth, diet, inflammation, clinical context, and intervention characteristics, while future research continues to refine and validate predictive approaches.
No takes yet. Share an insight, caveat, or question.
Basaca et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: